Evicenter
MarkdownMedical informationP&T meetings
Lanifibranor (IVA337)

Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Manufacturer
Inventiva
Last updated
220 sources

Section 4 of 6

Clinical evidence

313 evidence topics · 54 sources

Study summaries

NATiV3

Objective
Location and study date
Study design
January 2023 protocol amendments replacing Part 2 with a separate outcomes trial in compensated cirrhosis
Eligibility criteria
Treatment
Study outcomes
Rationale for using MASH resolution and fibrosis improvement of at least one stage as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Concomitant SGLT2 inhibitor and GLP-1 receptor agonist use at baseline in the NATiV3 main cohort compared with NATIVE, company slides
Co-medication at baselineNATiV3 (main cohort)NATIVE
SGLT2 inhibitor, yes“10.0%”“2.8%”
SGLT2 inhibitor, no“90.0%”“97.2%”
GLP-1 receptor agonist, yes“14.0%”“0.0%”
GLP-1 receptor agonist, no“86.0%”“0.0%”
Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary: results not yet reported and blinded safety information

The ClinicalTrials.gov record gives an actual primary completion date of 2026-09-29 and an estimated study completion date of 2027-09-30. All participants had completed the 72-week treatment period, and Inventiva expected to report topline results in the fourth quarter of 2026. The safety information available comes from company statements on Data Monitoring Committee reviews: one review used safety data from more than 500 participants, including participants treated with lanifibranor for more than 72 weeks; another used unblinded data from more than 900 participants randomized in the main and exploratory cohorts; and at another the data were unblinded to the committee and remained blinded with respect to the company.

Summary: histologic surrogate endpoint, endpoint naming, and reader variability
  • The primary outcome is histologic: resolution of NASH and improvement of fibrosis at week 72, defined by NASH CRN scores for ballooning of 0, inflammation of 0 to 1, and a fibrosis decrease of at least 1 stage. Inventiva states that accelerated approval and conditional authorization, even if granted, require completion of the trial to obtain full approval.
  • The January 2023 protocol amendments replaced the planned Part 2 of NATiV3, a clinical outcome trial in approximately 2,000 participants with F2 and F3 fibrosis for a maximum of seven years, with a separate event-driven phase 3 outcome trial in participants with compensated cirrhosis. The Form 20-F states that the FDA's guidance during a consultation preceding the amendments was to continue NATiV3 as originally planned, and that the FDA did not object to the amendments.
  • Sources name the endpoints differently. The ClinicalTrials.gov record names the composite of NASH resolution and fibrosis improvement as the primary outcome, and the investor and analyst day presentation names the composite as the primary endpoint and the two single histologic endpoints as key secondary endpoints. The financing terms in the Form 20-F describe the two single endpoints as “key primary endpoint or key secondary endpoint”. The original registry version (April 2021) titled the primary measure "Resolution of NASH" while defining it as the composite. Efficacy for the accelerated approval of resmetirom was determined on the two single endpoints, and the EMA reflection paper states that efficacy for both endpoints (resolution of NASH and improvement of fibrosis by at least 1 stage) should be demonstrated in co-primary fashion.
  • Davison et al. reported inter-reader unweighted kappas of 0.396 for NASH resolution without worsening fibrosis and 0.366 for fibrosis improvement without worsening NASH, and simulations in which unreliable endpoints and inclusion criteria reduced study power from >90% to as low as 40%.
Summary: enrollment figures, protocol amendments, and the extension period
  • Enrollment figures differ by source and date. The ClinicalTrials.gov record gives an estimated enrollment of 1000 (2000 in the April 2021 version). Inventiva reports 1,009 participants in the main cohort and 410 in the exploratory cohort, exceeding the original targets of 969 and 350. The Form 20-F anticipates an NDA based on histologic endpoints in approximately 950 patients, and the NATiV3 design release planned the histology analysis in approximately 900 patients.
  • The January 2023 amendments reduced the number of biopsies per participant from three to two and the trial duration a participant consents to from 7 years to 72 weeks. In 2022, recruitment was put on hold in Ukraine and all planned sites in Russia were removed.
  • A treatment-related suspected unexpected serious adverse reaction of elevated aminotransferases, with biopsy results compatible with autoimmune hepatitis, led to a voluntary pause in screening and randomization, an amendment excluding newly screened patients diagnosed with or predisposed to autoimmune liver or thyroid disease, and liver monitoring every 6 weeks. Before the pause, 913 participants had been randomized, including 731 in the main cohort.
  • The ClinicalTrials.gov and EU Clinical Trials Information System records describe the 48-week Part B extension as double-blind; the company's last patient visit release describes it as open-label, with all participants, including those originally randomized to placebo, receiving lanifibranor.
Summary: enrolled population and generalizability
  • Inventiva reported a recent screen failure rate of approximately 80% in December 2023, and the Form 20-F states that a higher than originally projected screen failure rate slowed enrollment.
  • The main cohort differs from the NATIVE population in company slides: type 2 diabetes 55% versus 42%, fibrosis stage F3 67.0% versus 34.8%, obesity 75% versus 65%, GLP-1 receptor agonist use at baseline 14.0% versus 0.0%, and SGLT2 inhibitor use 10.0% versus 2.8%.
  • As of December 2023, approximately 70% of participants randomized in the main and exploratory cohorts were from the United States, approximately 20% from Europe, and approximately 10% from Latin America and the rest of the world.
  • Exclusion criteria include HbA1c >9% at screening, current insulin treatment, history of heart failure with reduced left ventricular ejection fraction, atrial fibrillation requiring anticoagulation, current approved treatment for NASH or obesity, thiazolidinedione treatment in the prior 12 months, and hemoglobin <11 g/dL in females or <12 g/dL in males.

NATIVE

Objective
Location and study date
Study design
Design details in the ClinicalTrials.gov record
FieldQuoted record
Study type“Interventional”
Phase“Phase 2”
Primary purpose“Treatment”
Allocation“Randomized”
Interventional model“Parallel Assignment”
Masking“Quadruple”
Enrollment“Enrollment (Actual) 247”
Eligibility criteria
Exclusion criteria in the ClinicalTrials.gov record

“History of sustained excess alcohol ingestion: daily alcohol consumption > 30 g/day (3 drinks per day) for males and > 20 g/day (2 drinks per day) for females.” (opens the source at this quote in a new tab)

“Unstable metabolic condition: Weight change > 5kg in the last three months, diabetes with poor glycemic control (HbA1c > 8.5%), introduction of an antidiabetic or of an anti-obesity drug/malabsorptive or restrictive bariatric (weight loss) surgery in the past 6 months prior to screening.” (opens the source at this quote in a new tab)

“Significant systemic or major illnesses other than liver disease, including congestive heart failure (class C and D of the American Heart Association , AHA), unstable coronary artery disease, cerebrovascular disease, pulmonary disease, renal failure, organ transplantation, serious psychiatric disease, malignancy that, in the opinion of the investigator, would preclude treatment with IVA337 and/or adequate follow up.” (opens the source at this quote in a new tab)

“Body mass index (BMI) >45 kg/m2.” (opens the source at this quote in a new tab)

“Type 1 diabetes and type 2 diabetic patient on insulin.” (opens the source at this quote in a new tab)

“Fasting Triglycerides > 300 mg/dL.” (opens the source at this quote in a new tab)

“History of, or current cardiac dysrhythmias and/or a history of cardiovascular disease event, including myocardial infarction, except patients with only well controlled hypertension. Any clinically significant ECG abnormality reported by central ECG reading.” (opens the source at this quote in a new tab)

“Osteopenia or any other well documented Bone disease. Patient without well documented osteopenia treated with vitamin D and/or Calcium based supplements for preventive reasons can be included.” (opens the source at this quote in a new tab)

Treatment
Study outcomes
Rationale for using SAF activity score decrease of at least 2 points without worsening of fibrosis as the primary endpoint
Secondary histologic and nonhistologic end points in the published report

“Secondary histologic end points included resolution of NASH (defined as a ballooning grade of 0 and a lobular inflammation grade of ≤1) and no worsening of fibrosis; improvement in fibrosis stage of at least 1 and no worsening of NASH (i.e., no worsening in either steatosis, ballooning, or lobular inflammation); Nonalcoholic Fatty Liver Disease Activity Score (NAS) improvement (defined as a decrease of ≥2 points from baseline to week 24 in the NAS, which is the sum of the scores for steatosis [range, 0 to 3], ballooning [range, 0 to 2], and lobular inflammation [range, 0 to 3], with higher scores indicating greater disease activity) and no worsening of fibrosis12; resolution of NASH and an improvement in fibrosis stage of at least 1 (a composite end point); change in scores for the components of the SAF and NASH CRN scoring system (steatosis, activity, inflammation, ballooning, and fibrosis); and change in the modified Ishak score.” (opens the source at this quote in a new tab)

“Nonhistologic secondary end points included changes in liver enzyme levels (alanine aminotransferase, aspartate aminotransferase, and γ-glutamyltransferase); changes in measures of glucose metabolism (fasting levels of glucose, insulin, and glycated hemoglobin and homeostatic model assessment of insulin resistance [HOMA-IR] index score); changes in lipid levels (total cholesterol, high-density lipoprotein [HDL] cholesterol, low-density lipoprotein [LDL] cholesterol, triglycerides, and apolipoprotein A1); change in adiponectin level; and changes in inflammatory markers (fibrinogen, high-sensitivity C-reactive protein, α2-macroglobulin, and haptoglobin).” (opens the source at this quote in a new tab)

Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Multiplicity adjustment, multiple imputation, and sensitivity analyses in the published report

“For statistical tests, the type I error risk was set at 5% (two-sided) in accordance with the protocol. Adjustments for multiplicity testing in the primary analysis were performed with the use of the Hochberg procedure; each active-treatment group was compared with the placebo group. No multiplicity adjustments for the secondary and exploratory end points were defined.” (opens the source at this quote in a new tab)

“Comparisons of histologic responses among the trial groups were performed with the use of the Cochran–Mantel–Haenszel test stratified according to diabetic status at baseline.” (opens the source at this quote in a new tab)

“The primary analyses that we report here were performed in the full analysis population with the use of multiple imputation for missing data, including missing or inadequate biopsy data at the end of the treatment period (see the Supplementary Appendix). We also report the analyses that were performed with the use of single imputation to treat missing data as nonresponses, as specified in the statistical analysis plan.” (opens the source at this quote in a new tab)

“In addition, sensitivity analyses were conducted on the basis of complete cases (i.e., those with biopsy samples available at both baseline and the end of assigned regimen), as specified in the statistical analysis plan. Other analyses were performed in the per-protocol population and in the subgroups defined according to significant (moderate) or advanced fibrosis and diabetic status.” (opens the source at this quote in a new tab)

Results
Participant disposition
Participant flow and reasons for not completing in the registry results
Milestone or reasonLanifibranor 1200mgLanifibranor 800mgPlacebo
Started“83”“83”“81”
Completed“77”“77”“74”
Not completed“6”“6”“7”
Adverse event“3”“3”“3”
Lost to follow-up“1”“1”“0”
Non compliance“0”“1”“1”
Use of prohibited drug“0”“0”“2”
Withdrawal by patient and adverse event non fatal“0”“1”“0”
Withdrawal by subject“2”“0”“1”
Baseline characteristics
Demographic and clinical characteristics at baseline, full analysis population
CharacteristicLanifibranor 1200 mg (N=83)Lanifibranor 800 mg (N=83)Placebo (N=81)Overall (N=247)
Female sex, no. (%)“49 (59)”“54 (65)”“41 (51)”“144 (58)”
Age, yr“52.2±13.8”“55.0±10.4”“53.4±13.1”“53.6±12.5”
White race, no. (%)“78 (94)”“80 (96)”“74 (91)”“232 (94)”
Weight, kg“93.0±19.9”“91.6±19.3”“95.1±17.3”“93.2±18.9”
Body-mass index“33.3±5.5”“32.5±5.5”“32.8±5.1”“32.9±5.4”
Type 2 diabetes mellitus, no. (%)“35 (42)”“33 (40)”“35 (43)”“103 (42)”
Median time between screening biopsy and randomization (range), mo“2.4 (0.5–7.0)”“2.6 (0.5–9.2)”“2.0 (0.5–7.4)”“2.3 (0.5–9.2)”
Steatosis grade“2.6±0.6”“2.6±0.7”“2.5±0.7”“2.5±0.7”
Lobular inflammation grade“1.5±0.5”“1.5±0.5”“1.5±0.5”“1.5±0.5”
Ballooning grade“1.8±0.4”“1.7±0.4”“1.8±0.4”“1.8±0.4”
Fibrosis stage“2.1±0.8”“2.1±0.8”“2.0±0.9”“2.1±0.8”
Fibrosis stage F2 or F3, no. (%)“63 (76)”“68 (82)”“57 (70)”“188 (76)”
SAF-A score“3.3±0.5”“3.2±0.5”“3.3±0.5”“3.3±0.5”
NAS“5.9±0.9”“5.9±1.0”“5.9±1.1”“5.9±1.0”
NAS ≥6, no. (%)“61 (73)”“63 (76)”“56 (69)”“180 (73)”
Alanine aminotransferase, IU/liter“63.6±43.4”“64.1±41.4”“56.9±31.6”“61.6±39.2”
Aspartate aminotransferase, IU/liter“43.9±24.8”“53.9±43.4”“43.3±24.1”“47.1±32.3”
γ-Glutamyltransferase, IU/liter“67.1±93.1”“101.6±146.1”“67.9±80.4”“78.9±111.2”
Fasting HDL cholesterol, mmol/liter“1.2±0.3”“1.3±0.3”“1.2±0.3”“1.2±0.3”
Fasting triglycerides, mmol/liter“2.0±0.9”“1.9±0.9”“2.0±0.8”“2.0±0.9”
Fasting glucose, mmol/liter“5.9±1.1”“6.2±1.8”“6.0±1.6”“6.0±1.5”
Glycated hemoglobin, %“6.1±0.7”“6.1±0.8”“6.0±0.7”“6.0±0.7”
Fasting insulin, pmol/liter“274.7±321.2”“231.9±191.9”“234.0±254.6”“246.9±260.7”
Age categories and race in the registry results
CharacteristicIVA337 1200mgIVA337 800mgPlaceboTotal
Age between 18 and 65 years“67”“69”“63”“199”
Age 65 years or older“16”“14”“18”“48”
American Indian or Alaska Native“0”“0”“2”“2”
Asian“2”“1”“2”“5”
Native Hawaiian or Other Pacific Islander“0”“1”“0”“1”
Black or African American“3”“1”“3”“7”
White“78”“80”“74”“232”
Region of enrollment in the registry results
CountryIVA337 1200mgIVA337 800mgPlaceboTotal
Bulgaria“17”“16”“22”“55”
France“15”“15”“9”“39”
United States“13”“11”“12”“36”
Belgium“10”“11”“11”“32”
Australia“3”“7”“3”“13”
Germany“7”“3”“3”“13”
Spain“3”“4”“5”“12”
Czechia“3”“2”“3”“8”
Canada“3”“1”“4”“8”
United Kingdom“3”“2”“2”“7”
Mauritius“2”“3”“2”“7”
Poland“1”“2”“3”“6”
Italy“3”“1”“1”“5”
Switzerland“0”“3”“1”“4”
Austria“0”“1”“0”“1”
Slovenia“0”“1”“0”“1”
Efficacy results
Key secondary histologic endpoints: multiple imputation

“Analyses were performed with multiple imputation of missing data.” (opens the source at this quote in a new tab)

“Resolution of NASH without worsening of fibrosis at week 24 from baseline was observed in 49% of patients who received the 1200-mg dose of lanifibranor, in 39% of patients who received the 800-mg dose, and in 22% of patients who received placebo (risk ratio for a response in the 1200-mg lanifibranor group vs. the placebo group, 2.2; 95% CI, 1.5 to 3.3; and risk ratio in the 800-mg lanifibranor group vs. the placebo group, 1.7; 95% CI, 1.1 to 2.7) (Figure 1 and Table S5).” (opens the source at this quote in a new tab)

“Improvement in fibrosis stage of at least 1 without worsening of NASH was observed in 48% of patients in the 1200-mg lanifibranor group, in 34% of patients in the 800-mg lanifibranor group, and in 29% of patients in the placebo group (risk ratio in the 1200-mg lanifibranor group vs. the placebo group, 1.7; 95% CI, 1.2 to 2.5; and risk ratio in the 800-mg lanifibranor group vs. the placebo group, 1.2; 95% CI, 0.7 to 1.9) (Figure 1).” (opens the source at this quote in a new tab)

“Resolution of NASH and improvement in fibrosis stage of at least 1 (composite end point) was observed in 35% of patients in the 1200-mg lanifibranor group, in 25% of patients in the 800-mg lanifibranor group, and in 9% of patients in the placebo group (risk ratio in the 1200-mg lanifibranor group vs. the placebo group, 4.0; 95% CI, 2.0 to 7.7; and risk ratio in the 800-mg lanifibranor group vs. the placebo group, 2.6; 95% CI, 1.2 to 5.5) (Figure 1).” (opens the source at this quote in a new tab)

“In this trial, a dose-dependent improvement in SAF-A score and its individual components was noted with lanifibranor.” (opens the source at this quote in a new tab)

“In this trial, other findings from the secondary end-point analyses suggest that the 1200-mg dose of lanifibranor may have led to a regression of fibrosis.” (opens the source at this quote in a new tab)

Primary and key secondary histologic endpoints: ITT and per-protocol populations, company topline release
Endpoint at week 24ITT placeboITT lanifibranor 800 mgITT lanifibranor 1200 mgPP placeboPP lanifibranor 800 mgPP lanifibranor 1200 mg
Number of participants“(N = 81)”“(N = 83)”“(N = 83)”“(N = 62)”“(N = 63)”“(N = 69)”
Decrease of at least 2 points in SAF activity score (primary)“27%”“41% P=0.061”“49% P=0.004*”“34%”“51% P=0.058”“55% P=0.015*”
Resolution of NASH and no worsening of fibrosis“19%”“33% P=0.043*”“45% P<0.001*”“23%”“40% P=0.039*”“49% P=0.002*”
Improvement of fibrosis by at least one stage and no worsening of NASH“24%”“28% P=0.53”“42% P=0.011*”“29%”“32% P=0.75”“46% P=0.04*”
Resolution of NASH and improvement of fibrosis“7%”“21% P=0.017*”“31% P<0.001*”“10%”“24% P=0.036*”“33% P=0.001*”
Decrease of at least 2 points in NAS and no worsening of fibrosis“32%”“52% P=0.01*”“64% P<0.001*”“40%”“62% P=0.02*”“71% P<0.001*”
Histologic endpoints: participants with a response, missing data counted as nonresponse, registry results
Outcome measure at 24 weeks (participants with a response)IVA337 1200mgIVA337 800mgPlacebo
Overall number of participants analyzed“83”“83”“81”
SAF-A decrease of at least 2 points with no worsening of CRN-F (primary)“41”“34”“22”
NASH improvement (NAS decrease of at least 2 points without worsening of fibrosis)“53”“43”“26”
NASH resolution and no worsening of fibrosis“37”“27”“15”
Improvement of fibrosis by at least 1 stage and no worsening of NASH“35”“23”“19”
Resolution of NASH and improvement of fibrosis by at least 1 stage“26”“17”“6”
Activity (SAF-A) improvement“62”“54”“40”
Steatosis (CRN-S) improvement“54”“46”“21”
Lobular inflammation (CRN-I) improvement“43”“34”“30”
Hepatocyte ballooning (CRN-B) improvement“60”“54”“37”
Fibrosis (CRN-F) improvement“36”“28”“22”
Modified Ishak fibrosis (ISHAK-F) improvement“41”“32”“25”
Liver enzymes: adjusted mean change at week 24, completers in the full analysis population
Change from baseline (95% CI)Lanifibranor 1200 mg (N=77)Lanifibranor 800 mg (N=77)Placebo (N=74)
Alanine aminotransferase, U/liter“−24.54 (−32.06 to −17.01)”“−26.08 (−33.67 to −18.50)”“−1.40 (−9.04 to 6.25)”
Aspartate aminotransferase, U/liter“−12.04 (−18.29 to −5.79)”“−15.11 (−21.43 to −8.80)”“−0.08 (−6.43 to 6.26)”
γ-Glutamyltransferase, U/liter“−27.87 (−38.88 to −16.86)”“−43.38 (−54.46 to −32.29)”“4.41 (−6.76 to 15.58)”
Lipids and apolipoproteins: adjusted mean change at week 24, completers in the full analysis population
Noninvasive tests of fibrosis, apoptosis, and steatosis: completers in the full analysis population
Serum biomarker signatures of histologic response: pooled lanifibranor arms

“Patients receiving lanifibranor were pooled, and those with liver biopsies were selected (n = 142). A panel of 65 biomarkers were evaluated by assessing baseline and absolute as well as relative changes at the end of treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The biomarkers included in E1 score (baseline adiponectin and ferritin; delta of matrix metalloproteinase 9 and transferrin), E2 score (baseline cytokeratin 18 Fragment M65; delta of hyaluronic acid, fructosamine, and alanine aminotransferase), and E3 score (baseline cytokeratin 18 Fragment M65 and gamma-glutamyl transferase; delta of aspartate aminotransferase, insulin, and urea) represented metabolic, apoptotic, and fibrosis aspects of the disease. These signatures provided good accuracy for the noninvasive identification of histologic response under lanifibranor with area under the receiver operating characteristic curve at 0.81 ± 0.08 for E1 score, 0.80 ± 0.08 for E2 score, and 0.81 ± 0.08 for E3 score.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Results from this analysis show evidence that baseline values and changes in selected serum biomarkers can aid in predicting histologic response in MASH under lanifibranor treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

Health-related quality of life and patient-reported outcomes
Safety results
Adverse event overview: full analysis population, treatment period
Event, number (percent)Lanifibranor 1200 mg (N=83)Lanifibranor 800 mg (N=83)Placebo (N=81)
At least 1 adverse event“62 (75)”“59 (71)”“50 (62)”
Mild“54 (65)”“51 (61)”“42 (52)”
Moderate“28 (34)”“20 (24)”“22 (27)”
Severe“3 (4)”“3 (4)”“3 (4)”
Adverse event related to active drug or placebo, as assessed by the investigator“23 (28)”“25 (30)”“19 (23)”
Adverse event that led to permanent discontinuation of the trial regimen“3 (4)”“4 (5)”“3 (4)”
Adverse event related to active drug or placebo that led to discontinuation“2 (2)”“1 (1)”“2 (2)”
Serious adverse event“7 (8)”“3 (4)”“3 (4)”
Death“0”“0”“0”
Serious adverse event related to active drug or placebo“0”“0”“2 (2)”
Serious postprocedural condition linked to biopsy procedure“3 (4)”“1 (1)”“0”
Most frequent adverse events by arm: full analysis population
Adverse event, number (percent)Lanifibranor 1200 mg (N=83)Lanifibranor 800 mg (N=83)Placebo (N=81)
Diarrhea“10 (12)”“8 (10)”“1 (1)”
Fatigue“11 (13)”“3 (4)”“8 (10)”
Nausea“7 (8)”“8 (10)”“3 (4)”
Weight gain“7 (8)”“8 (10)”“0”
Peripheral edema“7 (8)”“5 (6)”“2 (2)”
Headache“7 (8)”“4 (5)”“4 (5)”
Abdominal pain“5 (6)”“4 (5)”“4 (5)”
Dizziness“6 (7)”“2 (2)”“3 (4)”
Anemia“6 (7)”“1 (1)”“0”
Constipation“5 (6)”“3 (4)”“6 (7)”
Increase in aminotransferase level“3 (4)”“5 (6)”“1 (1)”
Body weight: weight change category at week 24 by arm, completers, congress poster
Weight at week 24PlaceboLanifibranor 800 mgLanifibranor 1200 mgLanifibranor pooled
Number of participants“73”“71”“73”“144”
Stable (2.5% or less)“61 (84%)”“41 (58%)”“32 (44%)”“73 (51%)”
Increase (more than 2.5%), placebo only“12 (16%)”“–”“–”“–”
Increase (2.5% to 5%)“–”“9 (13%)”“14 (19%)”“23 (16%)”
Increase (more than 5%)“–”“21 (30%)”“27 (37%)”“48 (33%)”
Serious adverse events: registry results
Study limitations
Summary: duration, sample size, histology reading, and sponsor role
  • Treatment lasted 24 weeks; the protocol states that 6 months is sufficient in a proof-of-concept study and limits the time on placebo.
  • The protocol planned 225 randomized participants (75 per arm) for at least 80% power with a two-sided alpha of 0.025, assuming a placebo responder rate of 10% and an excess responder rate of 20%. The placebo response on the primary endpoint was 33% in the multiple imputation analysis of the journal report and 27% in the intention-to-treat population of the company topline release. A total of 247 participants were randomized (83, 83, and 81) out of 868 screened.
  • All biopsy samples were read by one pathologist who was unaware of timing and group assignment.
  • No fibrosis-stage inclusion criterion was set other than exclusion of cirrhosis; 188 participants (76%) had stage F2 or F3 fibrosis, and results in this group come from a subgroup analysis.
  • The journal report states that the validity of the SAF-A score as a surrogate for long-term outcomes “warrants further study”, and that changes in noninvasive biomarkers should be interpreted with caution, “particularly in short-term trials”.
  • The sponsor designed the trial, monitored the sites, collected the data, and analyzed the data.
Summary: missing biopsies, analysis methods, protocol changes, and figures that differ by source
  • Week 24 biopsies were missing for 34 participants (11 at 800 mg, 9 at 1200 mg, and 14 with placebo). The protocol specified that an amendment would be submitted to increase the sample size if end-of-study slides were unavailable or uninterpretable in more than 5% of participants.
  • The protocol's primary rule counted missing data as nonresponse; the journal report's primary analysis used multiple imputation. With multiple imputation, the primary endpoint was met by 55% with 1200 mg and 48% with 800 mg versus 33% with placebo (P=0.007 and P=0.07). The company topline release (intention-to-treat, all randomized) gives 49% (P=0.004) and 41% (P=0.061) versus 27%, and the registry, counting missing data as nonresponse, gives 41 of 83, 34 of 83, and 22 of 81 responders. The journal report states that nonresponder imputation and complete-case results were similar.
  • No multiplicity adjustments were defined for secondary and exploratory end points. The cardiometabolic analyses of Cooreman et al. had no multiplicity adjustment, are considered exploratory, and include post hoc analyses.
  • Protocol version 5.0, dated July 9, 2019, updated the secondary endpoints. The registry states that the last participant was recruited in March 2019, and the journal report gives a screening period of February 2017 through July 2019.
  • The selection period is 3 days to 4 weeks in the protocol and 10 days to 4 weeks in the registry.
  • Discontinuations for adverse events are 3 (4%), 4 (5%), and 3 (4%) in the journal report (1200 mg, 800 mg, placebo) and 3, 3, and 3 in the registry participant flow, which lists one further 800 mg participant under “Withdrawal by patient and adverse event non fatal”.
Summary: enrolled population and generalizability
  • Of 247 participants, 232 (94%) were White and 103 (42%) had type 2 diabetes. By registry region of enrollment, 55 were enrolled in Bulgaria, 39 in France, and 36 in the United States.
  • The protocol required GLP-1 receptor agonists, vitamin E, fibrates, and PPAR gamma agonists to be stopped before randomization, and the registry excluded participants with type 2 diabetes on insulin, HbA1c >8.5%, or body mass index >45 kg/m2.
  • Cooreman et al. state that participants who meet study entry criteria may not represent all patients seen in varying practice environments.

LEGEND

Objective
Location and study date
Study design
Design details in the ClinicalTrials.gov record
Eligibility criteria
Treatment
Study outcomes
Rationale for using change in HbA1c as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics, glycemic stratum, and body size in the ClinicalTrials.gov baseline table
CharacteristicLanifibranor 800 mgLanifibranor 800 mg plus empagliflozin 10 mgPlaceboTotal
Participants“12 participants”“13 participants”“14 participants”“39 participants”
Age, years, mean (SD)“55.1(11.45)”“54.2(13.48)”“54.7(13.01)”“54.6(12.38)”
Female, n“6”“8”“7”“21”
White, n“10”“10”“9”“29”
Hispanic or Latino, n“7”“4”“7”“18”
HbA1c ≥7.5%, n“8”“8”“9”“25”
Weight, kg, mean (SD)“93.30(11.614)”“103.30(12.437)”“94.50(21.269)”“97.06(16.213)”
BMI, kg/m2, mean (SD)“33.34(2.282)”“37.62(4.300)”“34.54(5.442)”“35.19(4.554)”
Median baseline characteristics in the poster
CharacteristicLanifibranorLanifibranor plus empagliflozinPlaceboTotal
Age (years)“55.5”“54.0”“55.5”“55.0”
Sex (% female)“6 (50)”“8 (62)”“7 (50)”“21 (54)”
Country (% USA)“11 (92)”“12 (92)”“12 (86)”“35 (90)”
Weight (kg)“93.9”“99.9”“97.4”“97.2”
HbA1c (%)“7.7”“8.0”“7.50”“7.7”
ALT (U/L)“53.0”“52.0”“33.0”“39.0”
HOMA-IR“9.4”“10.9”“16.3”“10.8”
cT1 (ms)“938”“926”“942”“931”
MRI-PDFF (%)“18.6”“21.1”“20.3”“19.3”
Efficacy results
Primary endpoint and HbA1c responders at the interim analysis, FAS and completers (company release, March 2024)
Interim analysis measurePlaceboLanifibranor 800 mgLanifibranor 800 mg plus empagliflozin 10 mg
HbA1c, LS mean absolute change from baseline to week 24 (%), FAS“0.26”“-1.14”“-1.59”
Participants, FAS“(n=9)”“(n=11)”“(n=10)”
HbA1c <6.5% at week 24 (%), completers“0”“55”“63”
HbA1c absolute decrease ≥1% at week 24 (%), completers“0”“64”“88”
Secondary endpoints at week 24, LS mean (95% CI), MMRM or ANCOVA (registry)
Additional liver, fibrosis, inflammatory, and metabolic biomarkers, LS means at week 24 with p values (poster)
LS mean at week 24 (p value versus placebo)LanifibranorLanifibranor plus empagliflozinPlacebo
GGT absolute change (IU/L)“-21.9 (0.010)”“-17.8 (0.015)”“22.8”
TIMP-1 absolute change (ng/mL)“-42.8 (0.040)”“-40.0 (0.056)”“-6.8”
Pro-C3 absolute change (ng/mL)“-1.26 (0.120)”“-3.54 (0.062)”“7.33”
hs-CRP relative change (%)“-32 (0.024)”“-48 (0.008)”“34”
Ferritin absolute change (µg/L)“-78 (0.002)”“-59 (0.022)”“-8”
Glucose absolute change (mmol/L)“-2.36 (0.005)”“-1.98 (0.022)”“-0.23”
Triglycerides relative change (%)“-26 (0.006)”“-27 (0.005)”“-2”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Mortality, serious adverse events, and selected other adverse events by arm (registry)
Event, affected / at risk (%)Lanifibranor 800 mgLanifibranor 800 mg plus empagliflozin 10 mgPlacebo
All-cause mortality“0/12 (0.00%)”“0/13 (0.00%)”“0/14 (0.00%)”
Other (not including serious) adverse events, total“10/12 (83.33%)”“9/13 (69.23%)”“8/14 (57.14%)”
Serious adverse event: haematuria“0/12 (0.00%)”“1/13 (7.69%)”“0/14 (0.00%)”
Anemia“2/12 (16.67%)”“0/13 (0.00%)”“1/14 (7.14%)”
Oedema peripheral“0/12 (0.00%)”“1/13 (7.69%)”“0/14 (0.00%)”
Headache“2/12 (16.67%)”“1/13 (7.69%)”“0/14 (0.00%)”
Nausea“1/12 (8.33%)”“2/13 (15.38%)”“0/14 (0.00%)”
Alopecia“2/12 (16.67%)”“0/13 (0.00%)”“0/14 (0.00%)”
Diabetes mellitus inadequate control“0/12 (0.00%)”“2/13 (15.38%)”“0/14 (0.00%)”
Blood glucose decreased“0/12 (0.00%)”“1/13 (7.69%)”“1/14 (7.14%)”
Study limitations
Summary: sample size, early stop of recruitment, open-label arm, and multiplicity
  • The protocol planned 63 participants (21 per group) for power close to 90%, assuming an HbA1c effect of 0.60% versus placebo. The protocol paused recruitment for an interim analysis once half of the planned participants were randomized; because the primary endpoint was met, recruitment was stopped. A total of 39 participants were treated (12 with lanifibranor, 13 with lanifibranor plus empagliflozin, and 14 with placebo) out of 213 screened.
  • The lanifibranor and placebo arms were double-blind, and the lanifibranor plus empagliflozin arm was open-label.
  • Treatment lasted 24 weeks, followed by a 4-week follow-up.
  • No alpha adjustment was applied for the interim analysis, the protocol describing the trial as an “exploratory proof-of-concept study”, and no multiplicity adjustment was made for secondary endpoints.
  • Inventiva does not expect to further study the combination of lanifibranor and empagliflozin.
Summary: population, endpoints, missing data, and figures that differ by source
  • MASH was diagnosed by historical histology or noninvasive methods, including cT1 thresholds on LiverMultiScan with or without MRI-PDFF. Participants had type 2 diabetes with HbA1c of 7.0% to 10.0% on diet, metformin, and/or a DPP-4 inhibitor; current or recent treatment with GLP-1 receptor agonists, insulin, or sulfonylureas was excluded. In the poster, 35 of 39 participants (90%) were enrolled in the United States.
  • The primary endpoint was the change in HbA1c; other endpoints were circulating biomarkers and MRI-based imaging.
  • In the placebo arm, 9 of 14 participants completed treatment (2 withdrawals, 2 lost to follow-up, 1 noncompliance). Two participants without post-treatment HbA1c values were excluded from the MMRM analysis, which used no explicit imputation, and 16 participants without week 24 VAT/SAT values were excluded from that ANCOVA analysis. Data after an intercurrent event (rescue medication in 2 participants and a significant diet change in 1) were excluded.
  • The interim analysis (FAS, n=11, 10, and 9) reported HbA1c changes of -1.14% and -1.59% with lanifibranor and the combination versus +0.26% with placebo; the final registry analysis reports -1.11, -1.54, and 0.16. The VAT/SAT ratio with placebo increased by 11% in the interim release and by 2% in the final poster. Completers in the combination arm are 11 in the poster and 12 in the registry participant flow.

NCT03459079

Objective
Location and study date
Study design
Design details in the ClinicalTrials.gov record
Eligibility criteria
Treatment
Study outcomes
Rationale for using intrahepatic triglyceride content by proton magnetic resonance spectroscopy as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline clinical and laboratory characteristics, FAS (published report)
CharacteristicPlacebo (n = 18)Lanifibranor (n = 20)
Age, years (mean ± SD)“58 ± 11”“61 ± 7”
Gender (% male/female)“28/72”“45/55”
White, n (%)“15 (83%)”“18 (90%)”
Weight, kg (mean ± SD)“99 ± 20”“96 ± 14”
Body mass index, kg/m2 (mean ± SD)“34.3 ± 6.2”“33.8 ± 5.1”
Fasting plasma glucose, mg/dl (mean ± SD)“122 ± 22”“130 ± 26”
HbA1c, % (mean ± SD)“7.0 ± 0.8”“6.8 ± 0.5”
Fasting plasma insulin, μU/ml (mean ± SD)“18.2 ± 12.7”“16.4 ± 8.6”
Triglycerides, mg/dl (mean ± SD)“196 ± 101”“175 ± 95”
HDL-C, mg/dl (mean ± SD)“43 ± 12”“42 ± 9”
Alanine aminotransferase, U/L (mean ± SD)“35 ± 27”“37 ± 20”
Aspartate aminotransferase, U/L (mean ± SD)“31 ± 19”“31 ± 14”
HOMA-IR (mean ± SD)“5.4 ± 3.4”“5.6 ± 3.2”
Adiponectin, μg/ml (mean ± SD)“5.0 ± 3.7”“4.5 ± 2.8”
Intrahepatic triglyceride content, % (mean ± SD)“18 ± 7”“21 ± 7”
Liver stiffness by MRE, kPa (mean ± SD)“2.5 ± 1.1”“2.8 ± 0.8”
Efficacy results
IHTG endpoints at week 24 (registry)
OutcomeLanifibranor (n = 20)Placebo (n = 18)
Absolute change in IHTG, LS mean (95% CI)“-8.7 (-11.3 to -6.0)”“-3.0 (-5.9 to -0.2)”
IHTG decrease of ≥30%, % of participants (95% CI)“65 (41 to 85)”“22 (6 to 48)”
NAFLD resolution (IHTG ≤5.5%), % of participants (95% CI)“25 (9 to 49)”“0 (0 to 19)”
Secondary metabolic endpoints at week 24, FAS adjusted LS means (published report)
Endpoint, FASLanifibranor, adjusted LS mean [95% CI]Placebo, adjusted LS mean [95% CI]Adjusted LS mean difference [95% CI]p value
Fasting hepatic glucose production, relative change (%)“-8 [-13; -4]”“4 [-1; 9]”“-13 [-20; -6]”“<0.001”
Hepatic IR index, relative change (%)“-26 [-37; -14]”“-7 [-19; 4]”“-18 [-34; -2]”“0.04”
Insulin-stimulated muscle glucose disposal, relative change (%)“30 [13; 46]”“0 [-17; 18]”“29 [5; 54]”“0.02”
Fasting plasma insulin, absolute change (μU/ml)“-3.1 [-5.5; -0.8]”“-0.0 [-2.5; 2.5]”“-3.1 [-6.5; 0.3]”“0.07”
Fasting plasma glucose, absolute change (mg/dl)“-17.2 [-27.4; -7.0]”“2.4 [-8.4; 13.2]”“-19.6 [-34.5; -4.7]”“0.01”
HOMA-IR, absolute change“-1.6 [-2.5; -0.7]”“-0.1 [-1.1; 0.8]”“-1.5 [-2.8; -0.2]”“0.03”
Adipo-IR, absolute change“-2.7 [-4.3; -1.2]”“-0.7 [-2.4; 0.9]”“-2.0 [-4.2; 0.3]”“0.08”
HbA1c, absolute change (%)“-0.7 [-1.0; -0.5]”“-0.1 [-0.3; 0.2]”“-0.6 [-1.0; -0.5]”“<0.001”
HDL-C, absolute change (mg/dl)“7.6 [4.4; 10.7]”“0.9 [-2.4; 4.3]”“6.6 [2.0; 11.3]”“0.006”
Adiponectin, fold change“2.4 [2.0; 2.7]”“1.0 [0.6; 1.4]”“1.4 [0.9; 1.9]”“<0.001”
Liver stiffness by transient elastography and MRE and plasma cytokeratin-18 at week 24 (registry)
OutcomeLanifibranorPlacebo
Liver stiffness by vibration controlled transient elastography, absolute change in kPa, LS mean (95% CI); n = 20 and 18“-1.49 (-2.66 to -0.31)”“-0.34 (-1.57 to 0.9)”
Liver stiffness by MRE, change in kPa, LS mean (95% CI); n = 18 and 18“0.23 (0.03 to 0.42)”“-0.06 (-0.25 to 0.13)”
Plasma cytokeratin 18, absolute change in IU/L, mean (SD); n = 20 and 18“-130.71(164.28)”“-70.21(230.39)”
Topline results, FAS and completers (company release, June 2023)
Completers, change from baseline to week 24Placebo (n=14)Lanifibranor 800 mg (n=14)
Absolute change in HbA1c, %“-0.2%”“-0.9”
Absolute change in fasting plasma insulin, μU/ml“-1.0”“-6.7”
Absolute change in hepatic insulin resistance index“-9.5”“-30.1”
Absolute change in basal endogenous glucose production (mg/kgLBM/min)“0.1”“-0.5”
Absolute change in muscle insulin-stimulated glucose disposal (mg/kg LBM/min)“-0.2”“+2.2”
Absolute change in HDL-C, mg/dl“-0.3”“6.3”
Absolute change in adiponectin, μg/mL“-0.2”“7.5”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-emergent adverse events by group (published report)
Event, n (%)Placebo (n = 18)Lanifibranor (n = 20)
Patients with TEAEs“17 (94%)”“18 (90%)”
Patients with severe TEAEs“0 (0%)”“1 (5%)”
Patients with serious adverse events“0 (0%)”“1 (5)”
TEAEs leading to drug discontinuation“2 (11%)”“4 (20%)”
Drug-related TEAE leading to discontinuation“2 (11%)”“3 (15%)”
Diarrhea“3 (17%)”“5 (25%)”
Elevated lipase level“3 (17%)”“5 (25%)”
Anemia“2 (11%)”“4 (20%)”
Leukopenia“1 (6%)”“3 (15%)”
Headache“1 (6%)”“3 (15%)”
Arthralgia“3 (17%)”“0 (0%)”
Oedema“0 (0%)”“1 (5%)”
Hypoglycemia“0 (0%)”“1 (5%)”
Decrease in eGFR“2 (11%)”“1 (5%)”
Mortality, serious adverse events, and selected other adverse events over 28 weeks (registry)
Event, affected / at risk (%)LanifibranorPlacebo
All-cause mortality“0/20 (0.00%)”“0/18 (0.00%)”
Serious adverse events, total“1/20 (5.00%)”“0/18 (0.00%)”
Other (not including serious) adverse events, total“18/20 (90.00%)”“17/18 (94.44%)”
Anaemia“4/20 (20.00%)”“2/18 (11.11%)”
Diarrhoea“5/19 (26.32%)”“3/18 (16.67%)”
Elevated lipase level“5/20 (25.00%)”“3/18 (16.67%)”
Edema“1/20 (5.00%)”“0/18 (0.00%)”
Study limitations
Summary: design, sample size, and enrolled population
  • The trial was single-center (Gainesville, Florida) and investigator-initiated, with financial support from Inventiva; the Inventiva research and development team had access to the database lock and assisted in the final analysis.
  • The planned number of participants was reduced during the trial on the basis of NATIVE steatosis results, to 15 per group completing treatment (power 0.80) and 33 to 34 randomized. A total of 38 participants were randomized (20 lanifibranor, 18 placebo), and 28 completed 24 weeks (14 [70%] and 14 [78%]). The registry states that the COVID epidemic greatly impacted recruitment and promoted dropout. The registry enrollment of 128 counts all enrolled participants, of whom 38 were randomized and 10 were healthy controls.
  • The registry gave an estimated recruitment period of about 9 months; randomization took place between August 2018 and April 2023.
  • The authors state that the study did not seek to recruit patients with MASH (fibrosis stage ≥F2) or to assess the role of improving insulin resistance on liver histology, for which the study was “not statistically powered”. The protocol states that the liver fat thresholds are assumed to correlate with histological changes based on the investigator's experience.
  • The discussion of the published report describes mild hyperglycemia with a mean baseline HbA1c of 7.2%; the baseline table gives 7.0 ± 0.8% with placebo and 6.8 ± 0.5% with lanifibranor. The male/female percentages at baseline were 28/72 with placebo and 45/55 with lanifibranor.
Summary: missing-data handling, multiplicity, and figures that differ by source
  • For missing week 24 IHTG data, the primary analysis used the baseline value under stated conditions; missing categorical data were imputed as failure, and missing data for the secondary metabolic endpoints were imputed by last observation carried forward.
  • The protocol defined no plan to control multiplicity for secondary or exploratory endpoints, which are considered exploratory.
  • The absolute change in IHTG differs by source. The 2023 congress poster reports -10.1% with lanifibranor versus -1.4% with placebo in the FAS and -12.4% versus -2.4% in completers; the published report gives -8.7% versus -3.0% (FAS) and -10.8% versus -4.0% (completers), and the registry gives -8.7 and -3.0. Both the poster and the published report give LS mean differences of -5.6% (FAS) and -6.9% (completers).